Hundreds of Millions Raised! Chinese Cardiac Intervention 'Potential Unicorn' Secures Series C Funding and Files for IPO

Recently, Wuhan Vickor Medical Technology Co., Ltd. ("Vickor") officially announced,The company has successfully completed the C-round financing, with an amount reaching hundreds of millions of RMB., by a well-known investment institution in Liangxi District, Wuxi CityBocapitalFully lead the investment.

According to reports,Vickor is an innovative medical device company dedicated to the field of minimally invasive interventions for structural heart disease and heart failure., With its core technical advantages in the cardiovascular field, since its establishment, Vickor MedicalCompleted 6 rounds of equity financing in total。

（As of the date of publication, the company's financing history was queried.）

This round of financing will provide strong financial support for Vickor in areas such as cardiovascular product development, market expansion, and international strategic layout.

Vickor Medical'sProduct LineCovering multiple cardiovascular treatment fields,And has won multiple "first-in-China" innovation labels，Including atrial shunt devices and various active devices for heart failure prevention and treatment, patent foramen ovale closure devices for cardiogenic stroke prevention, transcatheter aortic valve replacement systems for treating valvular diseases, as well as related surgical accessory consumables, which are undoubtedly pivotal in the field of interventional cardiology."Potential Unicorn"。

Among them, in November 2023,Vickor's D-shant® Atrial Shunt Device Receives FDA "Breakthrough Device" Designation。The ProductIt is China's first domestically developed implantable atrial shunt product, featuring an inward-folded metal stent design, about the size of a coin, with excellent radial support. Currently, this product has entered the NMPA "Special Review Procedure for Innovative Medical Devices."

Another self-developed product that has been launched isNew Generation PFO Occluder D-shufo®, which received NMPA registration approval in February this year,It is the only "single rivet + coating" second-generation PFO occluder previously approved for marketing in China., and has successfully completed more than a hundred commercial implants in 18 provinces and cities across China.

(Image source: Vickor Medical)）

According to Sullivan data statistics, the number of patients with aortic stenosis and aortic regurgitation in China was 4.4 million and 3.9 million respectively in 2020. It is estimated that by 2030, the number of patients with these two diseases will reach 5.2 million and 4.6 million respectively, with compound annual growth rates of 2.2% and 2.4% from 2020 to 2025.

And related therapeutic surgical catheter initiativeTranscatheter Aortic Valve Replacement (TAVR)The market penetration rate is approximately 0.3%, while the penetration rate in the U.S. market is 23.4%, by comparison.There is still a large market growth space for TAVR in China.。PredictionIn 2025, ChinaTAVRThe market size will reach 5.056 billion yuan.

According to reports,The product is planned to be launched in 2027., which can meet the needs of at least 10,000 surgeries every year. Currently, Vickor has established a complete production line for the entire series of valves, used for batch production and manufacturing of products.

With the completion of a new round of financing, the founder of Vickor stated that this funding would bring more resources and support to the company, helping it further strengthen its efforts in the cardiovascular medical device field.